Q1 Earnings Forecast for SLN Issued By HC Wainwright

Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) – Investment analysts at HC Wainwright issued their Q1 2027 earnings estimates for Silence Therapeutics in a research report issued on Wednesday, June 17th. HC Wainwright analyst P. Trucchio expects that the company will post earnings per share of ($0.39) for the quarter. HC Wainwright currently has a “Buy” rating and a $75.00 target price on the stock. The consensus estimate for Silence Therapeutics’ current full-year earnings is ($0.95) per share. HC Wainwright also issued estimates for Silence Therapeutics’ Q2 2027 earnings at ($0.48) EPS, Q3 2027 earnings at ($0.39) EPS and Q4 2027 earnings at ($0.45) EPS.

Silence Therapeutics (NASDAQ:SLN) last released its quarterly earnings results on Friday, May 8th. The company reported ($0.32) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.14). The company had revenue of $0.42 million for the quarter, compared to analyst estimates of $1.26 million. Silence Therapeutics had a negative return on equity of 105.34% and a negative net margin of 8,943.86%.

Several other equities analysts also recently weighed in on SLN. Jefferies Financial Group upgraded Silence Therapeutics to a “strong-buy” rating in a research report on Wednesday, March 18th. William Blair reiterated an “outperform” rating on shares of Silence Therapeutics in a research report on Monday, March 2nd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Silence Therapeutics in a report on Tuesday, April 21st. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $55.00.

Silence Therapeutics Trading Up 0.7%

SLN stock opened at $6.76 on Thursday. Silence Therapeutics has a 12-month low of $4.19 and a 12-month high of $8.40. The business’s 50-day moving average is $6.76 and its 200 day moving average is $6.10. The stock has a market cap of $319.34 million, a price-to-earnings ratio of -4.25 and a beta of 1.48.

Institutional Trading of Silence Therapeutics

Several large investors have recently added to or reduced their stakes in the stock. EHP Funds Inc. acquired a new stake in shares of Silence Therapeutics in the 3rd quarter worth $55,000. XTX Topco Ltd acquired a new position in shares of Silence Therapeutics during the 4th quarter valued at about $71,000. China Universal Asset Management Co. Ltd. grew its holdings in shares of Silence Therapeutics by 65.9% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 13,653 shares of the company’s stock valued at $83,000 after purchasing an additional 5,421 shares during the period. Citadel Advisors LLC purchased a new stake in shares of Silence Therapeutics in the third quarter valued at about $112,000. Finally, Massar Capital Management LP acquired a new stake in Silence Therapeutics during the second quarter worth about $115,000. 98.73% of the stock is currently owned by hedge funds and other institutional investors.

About Silence Therapeutics

Silence Therapeutics plc is a clinical-stage biotechnology company focused on the discovery and development of ribonucleic acid interference (RNAi) therapeutics. Leveraging its proprietary EnCore lipid nanoparticle delivery platform, the company aims to silence disease-causing genes in the liver and other tissues. Silence’s technology is designed to enhance targeted delivery of small interfering RNA (siRNA) molecules, with the goal of achieving durable therapeutic effects and improved safety profiles compared with traditional drug modalities.

The company’s lead product candidates include SLN360, an siRNA therapeutic designed to reduce lipoprotein(a) levels for cardiovascular risk reduction, and SLN124, aimed at treating hereditary hemochromatosis and beta-thalassemia by modulating iron metabolism.